Title Slide of Paul Davis' talk at the 7th Annual World ADC Summit in San Diego, given October 11, 2016. The talk is titled "Using the dPEG as the Framework to Uniquely Load and Protect Payloads in an ADC Format with dPEG Single Molecule Precision"

Our World ADC 2016 Presentation

The World ADC Summit in San Diego was held October 10-13, 2016. This was the 7th Annual World ADC Summit. On October 11, 2016, our company president, Paul D. Davis, presented his talk titled, “Using the dPEG® as the Framework to Uniquely Load and Protect Payloads in an ADC Format …with dPEG® single molecule precision.” See Figure 1.

Title Slide of Paul Davis' talk at the 7th Annual World ADC Summit in San Diego, given October 11, 2016. The talk is titled "Using the dPEG as the Framework to Uniquely Load and Protect Payloads in an ADC Format with dPEG Single Molecule Precision"
Figure 1: Title Slide of Paul Davis’ talk at the 7th Annual World ADC Summit in San Diego, given October 11, 2016.

The World ADC Summit is the premiere conference for discussing antibody drug conjugates (ADCs). Quanta BioDesign, Ltd. has attended every summit in San Diego since they began.

First, Paul discussed dPEG® chemistry (what it is and why you need it). Then he provided a great visual visual contrast between standard polydispersed PEGs and discrete PEGs (dPEG®s). Even with a dispersity (PDI) of 1.01, the number of different species in the dispersed PEG is astonishingly large! See Figure 2.

Slide showing the difference in mass spectra between one of Quanta BioDesign's dPEG® products and a comparably sized traditional (dispersed) PEG with PDI=1.01.
Figure 2: Slide showing the difference in mass spectra between one of Quanta BioDesign’s dPEG® products and a comparably sized traditional (dispersed) PEG with PDI=1.01.

The Highlight of our World ADC Presentation

In addition, and as the highlight of his talk, Paul discussed our new, patent-pending Sidewinder™ dPEG® platform. See Figure 3, below. This revolutionary new platform is designed for our customers who are developing ADC products. Sidewinder™ provides a stable, non-immunogenic platform with diverse reactive groups to allow conjugation of useful diagnostic or therapeutic compounds onto the platform. In order to optimize physiochemical properties such as pharmacokinetics (PK), pharmacodynamics (PD), and biodistribution (BD), modulating arms extend from the distal end of the platform. And these arms can be tailored to our customers’ precise needs.

Slide from Paul Davis' talk at the 7th Annual World ADC Summit, given October 11, 2016, in which Paul discusses the general platform for our new, patent-pending Sidewinder™ platform for drug delivery.
Figure 3: Slide from Paul Davis’ talk at the 7th Annual World ADC Summit, given October 11, 2016, discussing the general platform for our new, patent-pending Sidewinder™ platform for drug delivery.

Paul also showed off a bit. For successful ADCs, a high drug-to-antibody ratio (DAR) is critical. As DAR increases, ADC efficacy increases. Our Applications group demonstrated that Herceptin® (trastuzumab) could be fully reduced and conjugated to eight (8) Sidewinder™ platforms. Each platform contained three loading points, giving us a proof-of-concept that a DAR of twenty-four (24) is possible with Sidewinder™. See Figures 4, 5, and 6, below. This was one of the highlights of the talk, and after the talk, our booth at World ADC was full of people wanting to know more about our product.

Schematic drawing of Herceptin® (trastuzumab) with 8 Sidewinder™ platforms, each with 3 loading points, giving a DAR of 24 for the ADC.
Figure 4: Schematic drawing of Herceptin® (trastuzumab) with 8 Sidewinder™ platforms, each with 3 loading points, giving a DAR of 24 for the ADC.
Cartoon drawing of Herceptin® (trastuzumab) conjugated to 8 Sidewinder™ platforms, each with 3 connection points, giving a DAR of 24.
Figure 5: Cartoon drawing of Herceptin® (trastuzumab) conjugated to 8 Sidewinder™ platforms, each with 3 loading points, giving a DAR of 24 for the ADC.
Data Showing That Herceptin® (trastuzumab) has been conjugated to 8 Sidewinder™ platforms, giving a DAR of 24 for the ADC
Figure 6: Data Showing That Herceptin® (trastuzumab) has been conjugated to 8 Sidewinder™ platforms, giving a DAR of 24 for the ADC.

Wrapping Up

Paul’s complete presentation for the 7th Annual World ADC Summit in San Diego is available on our company page on LinkedIn and also on my page on SlideShare. We invite you to take a look at the whole presentation and then add comments, either on LinkedIn, SlideShare, or below. We’re in business to serve you, and we want to hear from you.

About the Author

Robert H. Woodman, Ph.D. is a Senior Product Development Scientist and the QC Manager for Quanta BioDesign, Ltd. You can connect with him on LinkedIn at https://www.linkedin.com/in/roberthwoodman, on Twitter at @RobertHWoodman and @QuantaBioDesign, and on Google+ at https://plus.google.com/+RobertWoodman. Feel free to contact him via social media.